Skip to main content
main-content
Top

19-10-2021 | Ankylosing spondylitis | News

approvalsWatch

Tofacitinib receives EMA support for ankylosing spondylitis

Author: Shreeya Nanda

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: Tofacitinib could soon be available in Europe for people with ankylosing spondylitis following a recommendation from the EMA to adopt a new indication for the drug.

According to the Committee for Medicinal Products for Human Use, the Janus kinase inhibitor is indicated for adult patients with active disease and an inadequate response to conventional treatment options.

This adds to the previous positive decisions for tofacitinib for the treatment of rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ulcerative colitis.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?